Nanolek

Executive Summary

Nanolek is a Russian biopharmaceutical company established in 2014, dedicated to the development, production, and commercialization of vaccines and biosimilars. Operating from a GMP-certified facility in Kirov, the company aims to improve public health by providing advanced medical technologies. With a strong presence in Russia's public procurement market, Nanolek focuses on addressing critical healthcare needs through affordable biologic therapies. Despite being at a pre-clinical stage, the company has built manufacturing capabilities and strategic partnerships to support future growth. The company's mission and operational foundation position it as a potential key player in the Russian biosimilar and vaccine landscape, though it remains early-stage with limited publicly disclosed pipeline details.

Upcoming Catalysts (preview)

• Q3 2026Initiation of clinical trials for lead biosimilar candidate40% success
• Q4 2026Securing additional public procurement contracts70% success
• TBDPartnership or licensing deal for vaccine technology30% success